







Previous studies have summarised evidence on health-related quality of life (HRQOL) for 
older people, identifying a range of measures that have been validated, but have not sought to 
present results by degree of frailty. Furthermore, previous studies did not typically use quality 
of life measures that generate an overall health utility score. Health utility scores are a 
necessary component of Quality Adjusted Life Year calculations used to estimate cost-
effectiveness of interventions. 
 
Methods  
We calculated normative estimates in terms of mean and standard deviation for EQ-5D-5L, 
SF-36 and SF-6D for a range of established frailty models. We compared response 
distributions across dimensions of the measures and investigated agreement using Bland-
Altman and Interclass Correlation techniques. 
 
Results 
EQ-5D-5L, SF-36 and SF-6D scores decrease and their variability increases with advancing 
frailty. There is strong agreement between EQ-5D-5L and SF-6D across the spectrum of 
frailty. Agreement is lower for people who are most frail, indicating that different 
components of the two instruments may have greater relevance for people with advancing 
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We recommend SF-36/SF-6D as an appropriate measure of HRQOL for clinical trials if fit 
older people are the planned target. In trials of interventions involving older people with 
increasing frailty we recommend that both EQ-5D-5L and SF36/SF6D are included, and are 





1. International guidelines identify development, evaluation and implementation of 
new interventions to improve QOL for older people with frailty as a key priority. 
 
2. Evidence on normative estimates and agreement for different measures of 
HRQOL across the spectrum of frailty is critical for designing interventions and 
cost-effectiveness evaluation. 
 
3. Researchers should consider using SF-36/SF-6D if fit older people are the planned 
target. In interventions involving older people with increasing frailty, both ED-5D 






The World Health Organisation (WHO) defines quality of life (QOL) as an ‘An individual’s 
perceptions of their position in life, in the context of the culture and value systems in which 
they live, and in relation to their goals, expectations, standards and concerns’1. International 
guidelines identify development, evaluation and implementation of new interventions and 
services to improve QOL for older people with frailty as a key priority2,3. A 2012 consensus 
report by the US Institute of Medicine has recommended a focus on QOL outcome measures 
for research and programme evaluation of interventions for people living with long-term 
health conditions4. 
Previous reviews have summarised evidence on health-related quality of life (HRQOL) 
measures for older people, identifying a wide range of measures that have been validated, but 
have not sought to present results stratified by degree of frailty5. More recently, reviews have 
focused on QOL for people living with frailty, but have identified limitations in the evidence 
base6. For example, although frailty is best understood as a graded condition, with evidence 
for the existence of mild frailty, or ‘pre-frailty’, that typically precedes development of more 
advanced frailty studies typically dichotomised frailty into ‘not frail’ and ‘frail’ categories6. 
Furthermore, included studies did not typically use QOL measures that enable generation of 
an overall health utility score, whereby individual health profiles are converted into single 
utility scores by applying pre-existing weights based on preferences of the general 
population. Health utility scores are a necessary component of Quality Adjusted Life Year 




Notably, no studies have evaluated the EuroQol 5-dimension health questionnaire (EQ-5D) in 
frailty as a well-established measure of HRQOL that enables generation of a health utility 
score. EQ-5D is the preferred UK National Institute for Health and Care Excellence (NICE) 
measure of HRQOL in adults 7 and is also the most evaluated HRQOL measure 
internationally8,9. Furthermore, although previous studies have evaluated the short-form 36 
item health questionnaire in frailty (SF-36)6, none evaluated the short-form 6 dimension (SF-
6D) health utility score that can be derived from the SF-36 for health economic modelling. 
Although the EQ-5D and SF-6D both enable derivation of a health utility score, and have 
been demonstrated to converge at the aggregate level, there is ongoing uncertainty regarding 
differences across patient groups and illness severity10. The two measures differ in terms of 
their dimensions, items, and preference weights and, therefore, can potentially assign 
different utility scores to the same individual 10,11. Furthermore, SF-6D has the potential to 
tap into broader aspects of HRQOL through its role and social functioning dimensions. These 
are particularly salient for the population of older people living with frailty as they often have 
complex health and social care needs and, thus, the social value of an intervention may be 
more important than health improvement. 
 
The absence of evidence on health utility scores for older people living with frailty is 
problematic, as normative estimates are needed for design of clinical trials to evaluate new 
interventions. Furthermore, HRQOL estimates for people living with different grades of 
frailty inform development of robust economic models, for example decision analytic cost 
effectiveness models that incorporate transition between frailty categories. Also, investigation 
of agreement between different HRQOL measures across different frailty categories would 





To report normative estimates for EQ-5D and SF-6D for a range of established frailty 
measures, compare response distribution across dimensions of the two HRQOL measures, 





Secondary analysis of prospective cohort data from the Community Ageing Research 75+ 
(CARE75+) study, collected between December 2014 and November 2018. 
 
Setting 
Multi-site, community-based cohort study, recruiting from UK general practices across a 
range of urban and rural areas, with wide sociodemographic representation12. 
 
Participants 
People aged 75 years and over and living at home were eligible. Care home residents, people 






1) Phenotype model 
The phenotype model of frailty, based on the five physical characteristics as reported in the 
original Cardiovascular Health Study (slow walking speed, weight loss, exhaustion, weak 
grip strength, low energy expenditure), uses standardised cut points13. Those with no 
characteristics were identified as fit, one or two characteristics as pre-frail and three to five 
characteristics as frail. 
 
2) Cumulative deficit model 
The research-standard 60 item frailty index (FI) is based on the cumulative deficit model of 
frailty and previously validated as part of the English Longitudinal Study of Ageing 
(ELSA)14. The FI score is calculated as an equally weighted proportion of the number of 
deficits present in an individual relative to the total possible. The FI groups individuals into 
four categories: very fit (FI score of 0-0.10); well (>0.10-0.14), vulnerable (>0.14-0.24), and 
frail (>0.24)15. 
 
3) Electronic frailty index (eFI) 
The eFI score is based on the cumulative deficit model of frailty, including 36 variables 
recorded in the primary care electronic health record (EHR) as part of routine care. The score 
is calculated as an equally weighted proportion of the number of deficits present in an 
individual relative to the total possible. The eFI enables identification of frailty categories: fit 
(0-0.12), mild frailty (0.12-0.24), moderate frailty (0.24-0.36), severe frailty (>0.36)16. 
 
HRQOL measures 
1) EuroQol 5-dimension health questionnaire, 5-level version (EQ-5D-5L) 
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The EQ-5D-5L five dimensions are: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has 5 levels of severity: no problems, slight problems, 
moderate problems, severe problems and extreme problems. The scores for each of the five 
dimensions are combined in a five digit number representing 3125 different health states that 
can be converted into a utility index ranging from -0.29 to 1 (0 for dead, 1 for perfect health 
and negative values for states worse than death) for use in economic evaluation17.  
 
2) SF-36 
The RAND short-form 36-Item Health Survey (SF-36) questionnaire includes 36 questions 
spanning eight health domains: physical functioning; bodily pain; role limitations due to 
physical health problems; role limitations due to personal or emotional problems; general 
mental health; social functioning; energy/fatigue; and general health perceptions. It also 
includes a single item that provides an indication of perceived change in health. The SF-36 
enables calculation of Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scores. SF-36 domain scores, PCS and MCS are on a 0-100 scale with 
higher scores indicating better health. 
 
3) SF-6D 
The SF-6D is a health utility score derived from 11 items of the SF-36 questionnaire. The 
items are converted into a six-dimension health state classification system, the SF-6D, with 
four to six levels, allowing for a total of 18,000 unique health states. Dimensions of SF-6D 
include physical functioning, role limitations, social functioning, pain, mental health, and 
vitality. The SF-6D index score has values ranging from 0.29 to 1, with lower values 




Methods of assessment 
All measures, except eFI scores, were obtained during face-to-face assessments in the 
participant’s own home. eFI scores were obtained directly from primary care Electronic 
Health Records (EHR). 
 
Bias 
All measures were collected using an electronic data capture system, and researchers were 
unable to review previous scores at follow-up time points for the same individual, limiting 
potential for assessment bias. 
 
Statistical methods 
We analysed the two HRQOL measures (EQ-5D-5L and SF-6D), the eight individual 
dimensions of SF-36, and the SF-36 PCS and MCS scores. We generated summary statistics 
for the entire sample and for frailty subsamples. We used qualitative, Bland Altman (BA), 
and quantitative, Intraclass Correlation (ICC), techniques to examine agreement between the 
two HRQOL measures.  
The ICC method formally tests significance of agreement in the sample under study. We used 
consistency of agreement ICC (CA-ICC) to account for the fact that the two utility scores are 
measured on different scales using a two-way mixed-effect ICC whereby the two HRQOL 
measures were modelled as fixed effects. The ICC method is dependent on the range of the 
measurement rather than the actual scale of measurement. Further, a high ICC is based on the 
assumption that discrepancies in measuring health utility are the same across the possible 
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range of outcomes. This might be considered too restrictive when we compare two health 
utility measures that, under an ordinality assumption, only need to preserve ranking to be 
equivalent and thus allow for non-constant biases across the different values of the indices. 
We therefore used an additional, qualitative measure of agreement, the Bland-Altman plot19 
20 which shows variation in agreement over the entire range of values. We performed two 
data transformations for the Bland-Altman analysis. First, to omit individual-specific 
clustering, we excluded all but the last observation for each individual. Second, we collapsed 
the data to averages of EQ-5D for each value of SF-6D and averages of SF-6D for each value 
of EQ-5D and retained one observation per individual for the analysis. 
We analysed the distributions of self-reported responses for individual dimensions of EQ-5D-
5L and SF-6D questionnaires for the whole sample and for subsamples based on frailty 
categories. We also examined correlation between dimensions of these two questionnaires 
using Spearman’s rank correlation coefficient. 
 
Missing data  





Data from 2472 assessments of 1038 individual CARE75+ participants are included, with 
75% of the study population aged 75–84 and slightly more women (52.7%). Based on the 
phenotype model, 20.2% of the sample were classified as fit, 51.4% pre-frail and 28.4% frail. 
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According to the cumulative deficit model 28.3% were classified as fit, 15.5% well, 30% 
vulnerable and 26.2% frail. The eFI distribution of frailty suggests that 22.4% were fit, 32.8% 
had mild frailty, 32.3% moderate frailty and 12.5% severe frailty (Table 1). 
 
Main results 
Quality of Life scores 
Table 2 presents normative data, in the form of means and standard deviations, for EQ-5D-
5L, SF-6D, PCS, MCS and the eight dimensions of SF-36 for the sample as a whole and by 
frailty categories.  
EQ-5D-5L and SF-6D utility scores consistently decrease with frailty. The EQ-5D-5L mean 
exceeds the SF-6D mean for all frailty categories. In general, the utility score mean difference 
decreases with advancing frailty across all three indices. 
Mean SF-36 scores decrease across all eight dimensions with increasing frailty. Similarly, 
SF-36 PCS scores decrease with increasing frailty. Although SF-36 MCS scores decrease 
with frailty, the differences between two consecutive groups for the Phenotype and eFI model 
are small (less than 2 points, or 4%) and somewhat larger (within 4.76 points, or 9.2%) for 
the Frailty Index. 
Variance estimates increase with frailty for most indices. This pattern is different on 
dimensions related to physical functioning. In particular, standard deviation is lower for the 
most frail category on PCS and two of its components (physical function and role limitations 
due to physical problems). 
Normative estimates were further stratified by age group and sex (Tables 4-7 in online 
appendix). Quality of life scores consistently decrease with age. Although men, in general, 
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report higher quality of life, women with advancing frailty and aged 85 and older report 
higher or similar EQ-5D, SF-6D, composite MCS and mental health and emotional role SF-
36 dimensions.  
Variance estimates increase with age and are higher for women. For individuals with 
advancing frailty aged 85 and older, the standard deviation is consistently lower on the 




CA-ICC results indicate stronger agreement between individual EQ-5D-5L and SF-6D across 
the entire sample (CA-ICC 0.61), compared with the generally lower CA-ICC estimates for 
individual frailty subgroups. (Table 3). The CA-ICC estimates are lower for the fit and frail 
categories of the phenotype model, but close in magnitude to the CA-ICC estimate for the 
entire sample for the pre-frail category.  The FI CA-ICC estimates for different frailty 
subgroups are low in magnitude. In the case of eFI, the CA-ICC is of similar magnitude 
across different frailty categories and closer in magnitude to the estimate for the entire 
sample. Precision of CA-ICC estimates (confidence interval (CI) width 0.05) is higher for the 
entire sample compared to frailty subsamples. 
The Bland-Altman plot (Figure 1) constructed using averages of one utility measure given the 
value of the other shows that there is systematic variation in EQ-5D-5L and SF-6D scores. 
Frailer individuals have lower average value of the two utility measurements, compared with 
fit individuals. Within the frail group, SF-6D scores are typically higher, compared to the 
EQ-5D-5L. Conversely, within the fitter group, EQ-5D-5L scores are typically higher. 
Results indicate increased greater variation in estimates with advancing frailty. 
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Given the differences in range and valuation of the EQ-5D and SF-6D utility measures we 
checked whether ranks of utility scores are better suited for the Bland-Altman analysis. The 
plot for ranks (in online appendix) shows higher variability in scores at better levels of health. 
This, at least partially, can be explained by the fact that the number of individuals with 
similar EQ-5D and SF-6D is significantly higher at the healthier end of the utility spectrum. 
As a result, the same error in measurement between EQ-5D and SF-6D will lead to larger 
discrepancy in terms of rank. The Bland Altman plot for ranks is also symmetric around 0 
suggesting there is no bias in predicting rank of one utility score using rank of the other. 
 
Correlation between EQ-5D-5L and SF-6D dimensions 
The correlations between similar dimensions 21 of the EQ-5D-5L and SF-6D utility indices 
are either high or moderate. The lowest correlations are observed between three pairs: (1) 
EQ-5D-5L pain/discomfort dimension and SF-6D mental health ( 0.189 ; (2) EQ-5D-5L 
anxiety/depression and SF-6D pain ( 0.190 ; and (3) EQ-5D-5L anxiety/depression and 
SF-6D vitality ( 0.190 .1 For each dimension of EQ-5D-5L a large proportion of the 
responses is concentrated in the top level. 37% of the overall study population reported 
scoring optimal HRQOL (EQ-5D score of 11111), but this was not observed with SF-6D with 
only 1% scoring the highest possible score. The predominant response for SF-6D physical 
functioning is level 2, while responses on pain and vitality have two equally probable levels 









Quality of life scores 
Our results indicate that mean EQ-5D-5L and SF-6D scores decrease, but overall variability 
of scores increases, with advancing frailty. Compared with EQ-5D-5L, SF-6D utility index 
value is higher for people with advancing frailty, consistent with previous research that has 
compared the two measures in more severe illness states10,11.  
Mean scores for the eight dimensions of SF-36 decrease with frailty. The decrease in mean 
scores is more notable for physical components of SF-36 and the overall physical component 
summary score, compared with the mental component summary score. Differences between 
means for the MCS are small with larger differences between groups of the FI model. As 
opposed to the EQ-5D-5L and SF-6D scores, variability estimates for the eight SF-36 
dimensions typically decrease with advancing frailty. Notable exceptions are the PCS and its 
physical function and physical-role components, where variability increases with advancing 
frailty. The variability of physical characteristics appears to decrease as individuals become 




The CA-ICC for the entire sample is larger than the frailty subgroup estimates as it is affected 
by the variability across a population. We found that variability within eFI categories and 
pre-frail category of the phenotype index is similar to the variability in the entire sample as 
indicated by CA-ICC estimates. The CA-ICC precision for the entire sample is larger as the 




We also observed stronger agreement between utility values at higher health levels on the 
Bland-Altman plot. Due to higher concentration of individuals at this end of the utility 
spectrum, the Bland-Altman plot based on ranks demonstrates higher variability. We 
conclude that value, not rank, is the appropriate measure of analysis.  
 
Response distribution 
The five level EQ–5D-5L has been shown to reduce the ceiling effects of the earlier three 
level version (EQ-5D-3L)22. This study however has identified that more than one in three 
older individuals (37%) scored in the top level on all five dimensions, indicating optimal 
HRQOL23, even though they had frailty classed as advanced by frailty models (8% by the 
Frailty Index and 15% by the Phenotype and eFI models), raising ongoing concern for ceiling 
effects with the five-level version in some groups of older people24.  
 
Limitations 
The findings in this study are based on a sample of individuals who are older than 75, live at 
home, with a relatively low prevalence of dementia. As a result, normative estimates and 
additional findings from this study cannot necessarily be extrapolated to older people living 
with dementia or care home residents25.  
In this study we assessed agreement between EQ-5D-5L and SF-6D. EQ-5D and SF-6D 
measures are used in healthcare decision making by NICE in the UK and health technology 
assessment agencies in other countries including Brazil, China, Norway, South Korea, and 
Spain9, with the EQ-5D being the preferred measure of HRQOL in adults. NICE currently 
does not recommend using the 5L valuation set26. Existing evidence27, however, suggests that 
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the 5L has superior measurement properties than the 3L and is preferable in population with 
multimorbidities, likely to have some similar characteristics to the population of older people 
living with frailty. As the cost-effectiveness results obtained from the two measures will 
likely differ, a sensitivity analysis using SF-6D to explore uncertainty in estimates for the 
population of individuals with increasing frailty is thus needed. 
 
Interpretation 
This study provides important information on normative estimates and agreement for 
different measures of health-related quality of life across the spectrum of frailty. These 
normative estimates can be used for robust sample size calculations by trialists investigating 
novel interventions for older people with frailty where health-related quality of life is the 
primary outcome of interest. 
 
Our findings indicate that health related quality of life decreases with advancing frailty when 
either EQ-5D-5L or SF-6D are used as the measure. There appears to be greater impact on 
physical health related quality of life than mental health-related quality of life, which may in 
part be explained by the greater emphasis on physical characteristics within frailty models.  
 
Overall health utility scores are more consistent for people who are fit, with greater 
variability in scores for people with increasing frailty, while physical components of the SF-
36 and composite PCS demonstrate consistent decline with frailty. Findings are consistent 
across different frailty measures and constructs. We have identified the possibility of a 




Findings indicate good agreement between EQ-5D-5L and SF-6D across the spectrum of 
frailty, lending support for the two measures identifying a common construct of health-
related quality of life in frailty. Agreement is lower for those who are most frail, indicating 
that different components of the two instruments may have greater relevance for people with 
advancing frailty in later life. 
We recommend that researchers consider using SF-36/SF-6D as an appropriate measure of 
health-related quality of life for clinical trials involving older people if there are concerns 
about the impact of ceiling effects for outcome measurement, for example if fit older people 
are the planned target. In trials involving older people with increasing frailty, where the social 
value of an intervention may be more relevant and ceiling effects less of a concern, we 
recommend that both EQ-5D-5L and SF-36/SF-6D are included as measures of health-related 
quality of life, and are used in sensitivity analysis as part of planned cost-effectiveness 
evaluation. Further research to clarify individual priorities for older people living with 
different degrees of frailty will help guide the future selection of appropriate tools for 
measurement of health-related quality of life in this population.  
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Figure1 shows the relationship between EQ-5D and SF-6D sample means difference for 
different values of the average of the two variables. 
 
